DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Comparison of the Safety and Comfort of AC-170

Information source: Aciex Therapeutics, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Normal Ocular Health

Intervention: AC-170 0.17% (Drug); AC-170 0.24% (Formulation 1) (Drug); AC-170 0.24% (Formulation 2) (Drug); Olopatadine hydrochloride 0.2% (Drug); Tears Naturale II (vehicle) (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Aciex Therapeutics, Inc.


The purpose of this study is to evaluate the safety and comfort of AC-170 compared to a placebo.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: Drop Comfort Score


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Able and willing to avoid the use of ocular medications or topical ocular

preparations within protocol specific time period. Exclusion Criteria:

- Known contraindications or sensitivities to the study medication or its components.

- Any ocular condition that, in the opinion of the investigator, could affect the

subjects safety or trial parameters.

- Use of disallowed medications during the period indicated prior to the study

enrollment or during the study.

Locations and Contacts

Andover Eye Associates, Andover, Massachusetts 01810, United States
Additional Information

Starting date: December 2011
Last updated: June 23, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017